Last chance to register for the next Respiratory and Allergy Learning Series event

Join Dr Steve Holmes, who will be chairing the MIMS Workshop: Respiratory and Allergy Learning Series taking place at The Coppid Beech Hotel, Berkshire on Tuesday, 10th September 2019.

This full-day MIMS workshop will cover the latest thinking in primary care management of respiratory and allergy disease. Workshop highlights include case-based learning in allergic airway disease and a focus on the patient through their allergy journey.

The programme will be delivered by expert speakers and is aimed at GPs, nurses and other healthcare professionals. Attendees will earn 4 hours of CPD* learning activity.

Click here to view the full programme and book your place

Places are available on a first-come, first-served basis. Register today to secure your place

These MIMS workshops are initiated, funded and reviewed by Mylan.

*The CPD credit award (4 learning credits) is recommended by MIMS Workshops for GPs and nurses based on attendance of the full meeting programme and reflecting on what attendees have learned. If you spend less time, we recommend claiming fewer credits. For pharmacists this qualifies as a planned learning activity.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...